Gilead Sciences Inc.

Access Program
Authors: Rangan, V. Kasturi; Lee, Katharine
Source: Harvard Business School
Year: 2010
Company Name: Gilead Sciences Inc.
Number of pages: 27

[This document has not yet been rated] [You must be signed in as faculty to rate this document]   553 views

Abstract:

Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients by the middle of 2009, the company's senior managers contemplated how to reach 2 million patients by 2012.